ADM Tronics Reports Second Quarter of Fiscal Year 2025 Results
ADM Tronics (OTCQB:ADMT) reported financial results for Q2 FY2025. Revenues increased 12% to $1,697,881 for the six months ended September 30, 2024, compared to $1,516,821 in the same period last year. The company posted income from operations of $118,423 versus a loss of $365,446 in the prior year period. For Q2, revenues grew 11% to $840,036, though operating loss was $45,858 compared to a $228,105 loss last year. The improvement was driven by increased revenues in engineering and chemical segments. The company continues R&D on its proprietary non-invasive musculoskeletal pain therapy device, planning an FDA 510(k) submission.
ADM Tronics (OTCQB:ADMT) ha riportato i risultati finanziari per il secondo trimestre dell'anno fiscale 2025. I ricavi sono aumentati del 12% a 1.697.881 $ per i sei mesi terminati il 30 settembre 2024, rispetto a 1.516.821 $ nello stesso periodo dell'anno precedente. L'azienda ha registrato un reddito operativo di 118.423 $ rispetto a una perdita di 365.446 $ nel periodo dell'anno passato. Per il secondo trimestre, i ricavi sono cresciuti dell'11% a 840.036 $, sebbene la perdita operativa sia stata di 45.858 $ rispetto a una perdita di 228.105 $ nell'anno scorso. Il miglioramento è stato guidato dall’aumento dei ricavi nei segmenti ingegneristico e chimico. L'azienda continua la ricerca e sviluppo sul suo dispositivo proprietario per la terapia del dolore muscoloscheletrico non invasiva, pianificando una presentazione alla FDA per il 510(k).
ADM Tronics (OTCQB:ADMT) reportó resultados financieros para el segundo trimestre del año fiscal 2025. Los ingresos aumentaron un 12% a 1,697,881 $ para los seis meses que terminaron el 30 de septiembre de 2024, en comparación con 1,516,821 $ en el mismo período del año pasado. La compañía presentó ingresos de operaciones de 118,423 $ frente a una pérdida de 365,446 $ en el período del año anterior. Para el segundo trimestre, los ingresos crecieron un 11% a 840,036 $, aunque la pérdida operativa fue de 45,858 $ en comparación con una pérdida de 228,105 $ el año pasado. La mejora fue impulsada por el aumento de ingresos en los segmentos de ingeniería y química. La compañía continúa con la I+D de su dispositivo terapéutico no invasivo para el dolor musculoesquelético, planificando una presentación de 510(k) a la FDA.
ADM Tronics (OTCQB:ADMT)는 2025 회계 연도 2분기 재무 결과를 보고했습니다. 2024년 9월 30일에 종료된 6개월 동안 수익이 12% 증가하여 $1,697,881에 달했으며, 이는 지난해 같은 기간의 $1,516,821와 비교됩니다. 회사는 118,423 달러의 운영 수익을 기록했으며, 이는 지난해 같은 기간의 365,446 달러 손실에 비해 개선된 것입니다. 2분기 동안 수익은 11% 증가하여 $840,036에 이르렀지만, 운영 손실은 45,858 달러로 지난해 228,105 달러 손실과 비교됩니다. 이러한 개선은 엔지니어링 및 화학 부문에서의 수익 증가에 의해 촉진되었습니다. 회사는 고유의 비침습적 근골격계 통증 치료 장치에 대한 연구 개발을 지속하고 있으며, FDA 510(k) 제출을 계획하고 있습니다.
ADM Tronics (OTCQB:ADMT) a annoncé les résultats financiers pour le deuxième trimestre de l'exercice 2025. Les revenus ont augmenté de 12 % pour atteindre 1.697.881 $ pour les six mois se terminant le 30 septembre 2024, contre 1.516.821 $ pour la même période l'année dernière. L'entreprise a enregistré un revenu opérationnel de 118.423 $ contre une perte de 365.446 $ au cours de la période de l'année précédente. Pour le deuxième trimestre, les revenus ont augmenté de 11 % pour atteindre 840.036 $, bien que la perte d'exploitation ait été de 45.858 $ par rapport à une perte de 228.105 $ l'année dernière. L'amélioration a été soutenue par une augmentation des revenus dans les segments d'ingénierie et chimique. L'entreprise continue ses recherches et développements sur son dispositif thérapeutique non invasif pour la douleur musculosquelettique, en prévoyant une soumission au FDA 510(k).
ADM Tronics (OTCQB:ADMT) hat die finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 bekannt gegeben. Die Einnahmen stiegen um 12 % auf 1.697.881 $ für die sechs Monate bis zum 30. September 2024, verglichen mit 1.516.821 $ im gleichen Zeitraum des Vorjahres. Das Unternehmen erzielte ein operatives Einkommen von 118.423 $ im Vergleich zu einem Verlust von 365.446 $ im gleichen Zeitraum des Vorjahres. Für das zweite Quartal stiegen die Einnahmen um 11 % auf 840.036 $, wobei der operative Verlust bei 45.858 $ lag, verglichen mit einem Verlust von 228.105 $ im Vorjahr. Die Verbesserung wurde durch gesteigerte Einnahmen in den Bereichen Ingenieurwesen und Chemie vorangetrieben. Das Unternehmen setzt die Forschung und Entwicklung seines proprietären nicht-invasiven Geräts zur Therapie von muskuloskeletalen Schmerzen fort und plant eine FDA 510(k) Einreichung.
- Revenue growth of 12% year-over-year for six months ended September 30, 2024
- Turned operating loss into profit for six-month period ($118,423 vs -$365,446)
- Significant improvement in gross profit ($939,685 vs $531,294)
- Net income of $219,481 for six months vs loss of $360,366 last year
- Q2 operating loss of $45,858
- Reduced revenues in electronics segment during Q2
- Increased operating expenses in Q2 ($464,640 vs $433,802)
NORTHVALE, NJ / ACCESSWIRE / November 14, 2024 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its second fiscal quarter ended September 30, 2024 of Fiscal Year 2025.
The upward trend in revenues, as reported in the Company's last quarterly report, continues for this second fiscal quarter of fiscal year ended March 31, 2025 with an increase in revenues of
Revenues for the six months ended September 30, 2024 were
Revenues for the three months ended September 30, 2024 were
Complete financial results are available in the Company's Quarterly Report on Form 10Q for September 30, 2024, available at www.sec.gov.
Financial Highlights
| Three Months Ended |
|
| Six Months Ended |
| |||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| |||||
Net revenues |
| $ | 840,036 |
|
| $ | 754,132 |
|
| $ | 1,697,881 |
|
| $ | 1,516,821 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Cost of sales |
| $ | 421,254 |
|
| $ | 547,980 |
|
| $ | 758,196 |
|
| $ | 985,527 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Gross Profit |
| $ | 418,782 |
|
| $ | 206,152 |
|
| $ | 939,685 |
|
| $ | 531,294 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Total Operating expenses |
| $ | 464,640 |
|
| $ | 433,802 |
|
| $ | 821,262 |
|
| $ | 896,740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Income (loss) from operations |
| $ | (45,858 | ) |
| $ | (227,650 | ) |
| $ | 118,423 |
|
| $ | (365,446 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Total other income (expense) |
| $ | (6,329 | ) |
| $ | (455 | ) |
| $ | 102,058 |
|
| $ | 5,080 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Net income (loss) |
| $ | (52,687 | ) |
| $ | (228,105 | ) |
| $ | 219,481 |
|
| $ | (360,366 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Basic and diluted per common share |
| $ | (0.00 | ) |
| $ | (0.00 | ) |
| $ | 0.00 |
|
| $ | (0.01 | ) |
Weighted average shares of common stock outstanding - basic and diluted |
|
| 67,588,492 |
|
|
| 67,588,492 |
|
|
| 67,588,492 |
|
|
| 67,588,492 |
|
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
Sign up for ADMT Investor News Updates emails by filling in the form at the bottom of the page at this link: https://admtronics.com/investor-relations/
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.
Investor Relations:
Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET
Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
View the original press release on accesswire.com
FAQ
What was ADMT's revenue growth in Q2 FY2025?
How much profit did ADMT report for the six months ended September 30, 2024?
What is ADMT's current development focus in medical devices?
